« Back
Home /
Hepatitis B surface antigen [HB5]

Hepatitis B surface antigen [HB5]

Item no.	20-272-193118
Manufacturer	GENWAY
Amount	0.5 mg
Category	Oncology Antibodies Primary Antibodies By Organ Hepatic Cancer
Type	Antibody
Clone	HB5
Specific against	other
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	GWB-195209
Similar products	20-272-193118
Available
Genway ID:	GWB-195209
Clone:	HB5
Isotype:	IgG1
Immunogen:	Recombinant HBsAg of ayw subtype.
Specificity:	Hepatitis B virus surface antigen. Reacts with the following HBsAg subtypes: ayw1 ayw2 ayw3 ayw4 ayr adw2 adw4 adrq+ adrq- ayw3 (Fer).
Target:	Hepatitis B surface antigen
Concentration:	6. 8 mg/ml
Purification Note:	Purified by Sepharose chromatography. Purity is tested by electrophoresis. Storage
Preservative:	0. 1% Sodium Azide. Constituents: PBS. pH 7. 4
Application Note:	IA: Use at an assay dependent dilution. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user. Myeloma: Sp2/0 Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid or core antigen (HBcAg) which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity specifically two pairs of sub specific determinants d/y and w/r allow the following combinations: adw ayw adr ayr.
Function:	The large envelope protein exists in two topological conformations one which is termed \' external\' or Le-HBsAg and the other \' internal\' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. It also assume fusion between virion membrane and cellular membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein (By similarity).
Function:	The middle envelope protein plays an important role in the budding of the virion. It is involved in the induction of budding in a nucleocapsid independent way. In this process the majority of envelope proteins bud to form subviral lipoprotein particles of 22 nm of diameter that do not contain a nucleocapsid (By similarity).
Subunit:	Li-HBsAg interacts with capsid protein and with HDV Large delta antigen. Isoform M associates with host chaperone CANX through its pre-S2 N glycan. This association may be essential for M proper secretion (By similarity).
Subcellular Location:	Virion membrane (By similarity).
Domain:	The large envelope protein is synthesized with the pre-S region at the cytosolic side of the endoplasmic reticulum and hence will be within the virion after budding. Therefore the pre-S region is not N-glycosylated. Later a post-translational translocation of N-terminal pre-S and TM1 domains occur in about 50% of proteins at the virion surface. These molecules change their topology by an unknown mechanism resulting in exposure of pre-S region at virion surface. For isoform M in contrast the pre-S2 region is translocated cotranslationally to the endoplasmic reticulum lumen and is N-glycosylated.
Ptm:	Isoform M is N-terminaly acetylated at a ratio of 90% N- and O-glycosylated at the pre-S2 region.
Ptm:	Myristoylated (By similarity). Biotechnology: Systematic vaccination of individuals at risk of exposure to the virus has been the main method of controlling the morbidity and mortality associated with hepatitis B. The first hepatitis B vaccine was manufactured by the purification and inactivation of HBsAg obtained from the plasma of chronic hepatitis B virus carriers. The vaccine is now produced by recombinant DNA techniques and expression of the S isoform in yeast cells. The pre-S region do not seem to induce strong enough antigenic response.
Similarity:	Belongs to the orthohepadnavirus major surface antigen family.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 0.5 mg

available

Delivery expected until 10/30/2025

Express Delivery: Save 2 days

Compare

Add to wishlist

Get an offer